Trial Profile
A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Camidanlumab tesirine (Primary)
- Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors ADC Therapeutics
- 12 Feb 2020 Status changed from completed to discontinued.
- 16 Oct 2018 Status changed from active, no longer recruiting to completed.
- 26 Jun 2018 Status changed from recruiting to active, no longer recruiting.